Baird downgraded Charles River to Neutral from Outperform with a price target of $191, down from $239. The analyst says the severity of the Discovery and Safety Assessment shortfall in Q2 “was drastically more than anticipated.” Charles River’s 2025 “seems a black box, and we can’t even pretend to be confident in forecasting,” the analyst tells investors in a research note. Baird is confident in eventual recovery, but is not sure if that’s six months or six quarters. As such, the firm is “certain that we would not be buying shares now.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- CRL Upcoming Earnings Report: What to Expect?
- Charles River, Autobahn Labs enter drug discovery collaboration
- Charles River removed from ‘Tactical Outperform’ list at Evercore ISI
- Charles River price target lowered to $239 from $271 at Baird
- Charles River added to ‘Tactical Outperform’ list at Evercore ISI